Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods
Imaging plays a key role is assessment of myeloma. Lytic bone lesions are optimally assessed using structural imaging however the structural changes lag in assessment of functional changes in the assessment of disease. Functional imaging with Fluoro Deoxy glucose (FDG) positron emission tomography computerized tomography (PET CT) is useful in assessment of high risk myeloma, provides prognostic information and is helpful in monitoring therapy response. However it is nonspecific and may not be optimal in assessing treatment response to immunotherapeutic agents. (Source: Seminars in Hematology)
Source: Seminars in Hematology - March 5, 2018 Category: Hematology Authors: Neeta Pandit-Taskar Source Type: research
MRD testing in multiple myeloma: the main future driver for modern tailored treatment
The past decade, several highly efficacious drugs have been approved for the treatment of multiple myeloma. Many of these newer drugs are less toxic than older chemotherapy drugs. Using modern combination therapy in newly diagnosed multiple myeloma patients, high proportions of newly diagnosed multiple myeloma patients obtain minimal residual disease (MRD) negativity and MRD testing has rapidly become an integral part of clinical trials focusing on patients in this setting. Only recently, MRD negativity was reported in clinical trials focusing on older newly diagnosed multiple myeloma patients (i.e., non-transplant candida...
Source: Seminars in Hematology - March 5, 2018 Category: Hematology Authors: Ola Landgren, Sydney X Lu, Malin Hultcrantz Source Type: research
Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease
The presence or absence of minimal residual disease (MRD) in patients with multiple myeloma (MM) has emerged as a useful marker to determine the depth of remission. MRD negativity as an endpoint has been shown to be associated with improved progression-free survival in many studies. MRD detection is therefore part of numerous clinical trial protocols for MM. At the present time, two methodologies are most widely accepted for MRD detection: (1) multicolor flow cytometry and (2) next-generation sequencing-based clonotype detection. (Source: Seminars in Hematology)
Source: Seminars in Hematology - March 1, 2018 Category: Hematology Authors: Johannes M. Waldschmidt, Praveen Anand, Birgit Knoechel, Jens G. Lohr Tags: Review Source Type: research
Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at MRD
The presence or absence of minimal residual disease (MRD) in patients with multiple myeloma (MM) has emerged as a useful marker to determine the depth of remission. MRD negativity as an endpoint has been shown to be associated with improved progression-free survival in many studies. MRD detection is therefore part of numerous clinical trial protocols for MM. At the present time, two methodologies are most widely accepted for MRD detection: i) multi-color flow cytometry, and ii) next-generation sequencing (NGS) -based clonotype detection. (Source: Seminars in Hematology)
Source: Seminars in Hematology - March 1, 2018 Category: Hematology Authors: Johannes M. Waldschmidt, Praveen Anand, Birgit Knoechel, Jens G. Lohr Source Type: research
Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease
Mass spectrometry methods that can detect low levels of monoclonal immunoglobulin in serum have recently been developed. These assays are based on the principle that each immunoglobulin has a unique amino acid sequence and therefore, has a unique mass. This mass can be used as a surrogate marker in order to monitor a patient ’s disease over time and at low levels. Here, we explain these methods, discuss their advantages and disadvantages and how they may be used to monitor monoclonal immunoglobulins for minimal residual disease detection in multiple myeloma. (Source: Seminars in Hematology)
Source: Seminars in Hematology - February 26, 2018 Category: Hematology Authors: Katie L. Thoren Source Type: research
Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease
Mass spectrometry methods that can detect low levels of monoclonal immunoglobulin in serum have recently been developed. These assays are based on the principle that each immunoglobulin has a unique amino acid sequence and therefore, has a unique mass. This mass can be used as a surrogate marker in order to monitor a patient ′s disease over time and at low levels. Here, we explain these methods, discuss their advantages and disadvantages and how they may be used to monitor monoclonal immunoglobulins for minimal residual disease detection in multiple myeloma. (Source: Seminars in Hematology)
Source: Seminars in Hematology - February 26, 2018 Category: Hematology Authors: Katie L. Thoren Source Type: research
Minimal residual disease detection of myeloma using sequencing of immunoglobulin heavy chain gene VDJ regions
After therapy or stem cell transplantation, multiple myeloma patients achieving complete response or stringent complete response can still have a significant risk of disease relapse. This highlights the importance of using highly sensitive laboratory methods for minimal residual disease detection and prognostication. Older methods such as allele-specific oligonucleotide real time quantitative polymerase chain reaction and fluorescent polymerase chain reaction have their drawbacks. Meanwhile, the recent generation of multiparametric flow cytometry and next-generation sequencing (NGS)-based detection methods currently offer ...
Source: Seminars in Hematology - February 23, 2018 Category: Hematology Authors: Caleb Ho, Maria E. Arcila Source Type: research
Minimal Residual Disease Detection of Myeloma Using Sequencing of IGH VDJ Regions
After therapy or stem cell transplantation, multiple myeloma patients achieving complete response or stringent complete response can still have a significant risk of disease relapse. This highlights the importance of using highly sensitive laboratory methods for minimal residual disease (MRD) detection and prognostication. Older methods such as allele-specific oligonucleotide real time quantitative polymerase chain reaction (ASO-RQ PCR) and fluorescent polymerase chain reaction (F-PCR) have their drawbacks. (Source: Seminars in Hematology)
Source: Seminars in Hematology - February 23, 2018 Category: Hematology Authors: Caleb Ho, Maria E. Arcila Source Type: research
Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
Azacitidine (AZA) treatment is effective treatment for patients with myeloid disorders, and factors predictive of treatment outcome are under investigation. Little is known about the effect of bone marrow fibrosis on response to AZA therapy. We, retrospectively, evaluated clinical predictors of overall survival (OS) and overall response rate (ORR) for patients treated with AZA in a real-life cohort. We evaluated 94 consecutive patients treated with AZA outside of clinical trials (75mg/m2/day for 7 days every 28 days; 5 + 2 + 2 schedule), from June 2009 to February 2016. (Source: Seminars in Hematology)
Source: Seminars in Hematology - February 21, 2018 Category: Hematology Authors: Gianluigi Reda, Marta Riva, Bruno Fattizzo, Ramona Cassin, Diana Giannarelli, Martina Pennisi, Alessandra Freyrie, Roberto Cairoli, Alfredo Molteni, Agostino Cortelezzi Tags: Research Article Source Type: research
Acquired Hemophilia A in Aged People: A Systematic Review of Case Reports and Case Series
Acquired hemophilia A (AHA) is a rare disease that requires urgent management. Currently, there is no consensus regarding optimal management in aged people. This systematic review aimed to describe diagnosis, clinical features, management, and endpoints in population aged 65 years or over with AHA.A literature search up to and including 31 May 2017 was performed in Medline, Embase, and Scopus. The search strategy on article titles comprised the following terms: “acquired” AND (“hemophilia A” OR “haemophilia A”). (Source: Seminars in Hematology)
Source: Seminars in Hematology - February 21, 2018 Category: Hematology Authors: Lidvine Godaert, Seendy Bartholet, S ébastien Colas, Lukshe Kanagaratnam, Jean-Luc Fanon, Moustapha Dramé Source Type: research
Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome
Incidence and effect on outcome of central nervous system (CNS) involvement in adult patients with acute myeloid leukemia (AML) is not clearly defined. To address this issue, 103 consecutive adult patients with newly diagnosed AML, regardless of neurologic symptoms, were submitted to a routine explorative lumbar puncture. Cerebrospinal fluid (CSF) samples were collected from 65 males and 38 females. All 103 CSF samples were examined by conventional cytology (CC) whereas 95 (92%) also by flow cytometry (FCM). (Source: Seminars in Hematology)
Source: Seminars in Hematology - February 21, 2018 Category: Hematology Authors: Maria Ilaria Del Principe, Francesco Buccisano, Stefano Soddu, Luca Maurillo, Mariagiovanna Cefalo, Alfonso Piciocchi, Maria Irno Consalvo, Giovangiacinto Paterno, Chiara Sarlo, Eleonora De Bellis, Annagiulia Zizzari, Gottardo De Angelis, Daniela Fraboni, Tags: Review Source Type: research
Bone marrow fibrosis and early hematological response as predictors of poor outcome in azacitidine treated high risk-MDS/AML patients
Azacitidine (AZA) treatment is effective treatment for patients with myeloid disorders, and factors predictive of treatment outcome are under investigation. Little is known about the impact of bone marrow (BM) fibrosis on response to AZA therapy. We retrospectively evaluated clinical predictors of overall survival (OS) and overall response rate (ORR) for patients treated with AZA in a real-life cohort. We evaluated 94 consecutive patients treated with AZA outside of clinical trials (75mg/m2/day for 7 days every 28 days; 5+2+2 schedule), from June 2009 –February 2016. (Source: Seminars in Hematology)
Source: Seminars in Hematology - February 21, 2018 Category: Hematology Authors: Gianluigi Reda, Marta Riva, Bruno Fattizzo, Ramona Cassin, Diana Giannarelli, Martina Pennisi, Alessandra Freyrie, Roberto Cairoli, Alfredo Molteni, Agostino Cortelezzi Tags: Research article Source Type: research
Acquired hemophilia a in aged people: A systematic review of case reports and case series
Acquired Hemophilia A (AHA) is a rare disease that requires urgent management. Currently, there is no consensus regarding optimal management in aged people. This systematic review aimed to describe diagnosis, clinical features, management, and endpoints in population aged 65 years or over with AHA.A literature search up to and including 31st May 2017 was performed in Medline, Embase, and Scopus. The search strategy on article titles comprised the following terms: “acquired” AND (“hemophilia A” OR “haemophilia A”). (Source: Seminars in Hematology)
Source: Seminars in Hematology - February 21, 2018 Category: Hematology Authors: Lidvine Godaert, Seendy Bartholet, Sebastien Colas, Lukshe Kanagaratnam, Jean-Luc Fanon, Moustapha Dram é Source Type: research
